Cargando…

TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p

SIMPLE SUMMARY: An estimated ~25–30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Girijesh Kumar, Dutta, Sayanika, Mahmud Syed, Mosharaf, Ramachandran, Sabarish, Sharma, Monica, Rajamanickam, Venkatesh, Ganapathy, Vadivel, DeGraff, David J., Pruitt, Kevin, Tripathi, Manisha, Nandana, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507954/
https://www.ncbi.nlm.nih.gov/pubmed/34638504
http://dx.doi.org/10.3390/cancers13195020
_version_ 1784581982141808640
author Patel, Girijesh Kumar
Dutta, Sayanika
Mahmud Syed, Mosharaf
Ramachandran, Sabarish
Sharma, Monica
Rajamanickam, Venkatesh
Ganapathy, Vadivel
DeGraff, David J.
Pruitt, Kevin
Tripathi, Manisha
Nandana, Srinivas
author_facet Patel, Girijesh Kumar
Dutta, Sayanika
Mahmud Syed, Mosharaf
Ramachandran, Sabarish
Sharma, Monica
Rajamanickam, Venkatesh
Ganapathy, Vadivel
DeGraff, David J.
Pruitt, Kevin
Tripathi, Manisha
Nandana, Srinivas
author_sort Patel, Girijesh Kumar
collection PubMed
description SIMPLE SUMMARY: An estimated ~25–30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms that propagate the t-NEPC phenotype is critical towards developing novel therapeutic strategies against advanced PCa. Further, the roles of extracellular vesicles (exosomes) and microRNAs—an increasingly recognized and key mode of propagation of the NEPC phenotype—remain elusive. Our studies reveal that TBX2 promotes SOX2- and N-MYC- driven t-NEPC through regulation of the intermediary factor—miR-200c-3p; and that TBX2/miR-200c-3p/SOX2/MYCN signaling can promote t-NEPC via both intracellular and exosome-mediated intercellular mechanisms. ABSTRACT: Deciphering the mechanisms that drive transdifferentiation to neuroendocrine prostate cancer (NEPC) is crucial to identifying novel therapeutic strategies against this lethal and aggressive subtype of advanced prostate cancer (PCa). Further, the role played by exosomal microRNAs (miRs) in mediating signaling mechanisms that propagate the NEPC phenotype remains largely elusive. The unbiased differential miR expression profiling of human PCa cells genetically modulated for TBX2 expression led to the identification of miR-200c-3p. Our findings have unraveled the TBX2/miR-200c-3p/SOX2/N-MYC signaling axis in NEPC transdifferentiation. Mechanistically, we found that: (1) TBX2 binds to the promoter and represses the expression of miR-200c-3p, a miR reported to be lost in castrate resistant prostate cancer (CRPC), and (2) the repression of miR-200c-3p results in the increased expression of its targets SOX2 and N-MYC. In addition, the rescue of mir-200c-3p in the context of TBX2 blockade revealed that miR-200c-3p is the critical intermediary effector in TBX2 regulation of SOX2 and N-MYC. Further, our studies show that in addition to the intracellular mode, TBX2/miR-200c-3p/SOX2/N-MYC signaling can promote NEPC transdifferentiation via exosome-mediated intercellular mechanism, an increasingly recognized and key mode of propagation of the NEPC phenotype.
format Online
Article
Text
id pubmed-8507954
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85079542021-10-13 TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p Patel, Girijesh Kumar Dutta, Sayanika Mahmud Syed, Mosharaf Ramachandran, Sabarish Sharma, Monica Rajamanickam, Venkatesh Ganapathy, Vadivel DeGraff, David J. Pruitt, Kevin Tripathi, Manisha Nandana, Srinivas Cancers (Basel) Article SIMPLE SUMMARY: An estimated ~25–30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms that propagate the t-NEPC phenotype is critical towards developing novel therapeutic strategies against advanced PCa. Further, the roles of extracellular vesicles (exosomes) and microRNAs—an increasingly recognized and key mode of propagation of the NEPC phenotype—remain elusive. Our studies reveal that TBX2 promotes SOX2- and N-MYC- driven t-NEPC through regulation of the intermediary factor—miR-200c-3p; and that TBX2/miR-200c-3p/SOX2/MYCN signaling can promote t-NEPC via both intracellular and exosome-mediated intercellular mechanisms. ABSTRACT: Deciphering the mechanisms that drive transdifferentiation to neuroendocrine prostate cancer (NEPC) is crucial to identifying novel therapeutic strategies against this lethal and aggressive subtype of advanced prostate cancer (PCa). Further, the role played by exosomal microRNAs (miRs) in mediating signaling mechanisms that propagate the NEPC phenotype remains largely elusive. The unbiased differential miR expression profiling of human PCa cells genetically modulated for TBX2 expression led to the identification of miR-200c-3p. Our findings have unraveled the TBX2/miR-200c-3p/SOX2/N-MYC signaling axis in NEPC transdifferentiation. Mechanistically, we found that: (1) TBX2 binds to the promoter and represses the expression of miR-200c-3p, a miR reported to be lost in castrate resistant prostate cancer (CRPC), and (2) the repression of miR-200c-3p results in the increased expression of its targets SOX2 and N-MYC. In addition, the rescue of mir-200c-3p in the context of TBX2 blockade revealed that miR-200c-3p is the critical intermediary effector in TBX2 regulation of SOX2 and N-MYC. Further, our studies show that in addition to the intracellular mode, TBX2/miR-200c-3p/SOX2/N-MYC signaling can promote NEPC transdifferentiation via exosome-mediated intercellular mechanism, an increasingly recognized and key mode of propagation of the NEPC phenotype. MDPI 2021-10-07 /pmc/articles/PMC8507954/ /pubmed/34638504 http://dx.doi.org/10.3390/cancers13195020 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Patel, Girijesh Kumar
Dutta, Sayanika
Mahmud Syed, Mosharaf
Ramachandran, Sabarish
Sharma, Monica
Rajamanickam, Venkatesh
Ganapathy, Vadivel
DeGraff, David J.
Pruitt, Kevin
Tripathi, Manisha
Nandana, Srinivas
TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p
title TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p
title_full TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p
title_fullStr TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p
title_full_unstemmed TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p
title_short TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p
title_sort tbx2 drives neuroendocrine prostate cancer through exosome-mediated repression of mir-200c-3p
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507954/
https://www.ncbi.nlm.nih.gov/pubmed/34638504
http://dx.doi.org/10.3390/cancers13195020
work_keys_str_mv AT patelgirijeshkumar tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT duttasayanika tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT mahmudsyedmosharaf tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT ramachandransabarish tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT sharmamonica tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT rajamanickamvenkatesh tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT ganapathyvadivel tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT degraffdavidj tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT pruittkevin tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT tripathimanisha tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p
AT nandanasrinivas tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p